PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 232 filers reported holding PDL BIOPHARMA INC in Q3 2014. The put-call ratio across all filers is 1.63 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $517,000 | +136.1% | 139,113 | +84.3% | 0.00% | +200.0% |
Q4 2018 | $219,000 | -59.0% | 75,499 | -62.8% | 0.00% | -66.7% |
Q3 2018 | $534,000 | +12.7% | 202,826 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $474,000 | +13.4% | 202,826 | +42.7% | 0.00% | 0.0% |
Q1 2018 | $418,000 | +7.2% | 142,097 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $390,000 | -18.9% | 142,097 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $481,000 | +37.0% | 142,097 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $351,000 | +118.0% | 142,097 | +99.9% | 0.00% | +200.0% |
Q1 2017 | $161,000 | +6.6% | 71,074 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $151,000 | -36.6% | 71,074 | 0.0% | 0.00% | -50.0% |
Q3 2016 | $238,000 | +6.7% | 71,074 | 0.0% | 0.00% | 0.0% |
Q2 2016 | $223,000 | -19.2% | 71,074 | +80.7% | 0.00% | -33.3% |
Q1 2015 | $276,000 | -9.2% | 39,323 | -0.3% | 0.00% | -25.0% |
Q4 2014 | $304,000 | +3.4% | 39,452 | 0.0% | 0.00% | 0.0% |
Q3 2014 | $294,000 | – | 39,452 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SMH CAPITAL ADVISORS INC | 81,713 | $176,000 | 0.39% |
BRANDES INVESTMENT PARTNERS, LP | 5,465,156 | $11,805,000 | 0.30% |
Crestline Management, LP | 875,000 | $1,890,000 | 0.30% |
West Family Investments, Inc. | 539,450 | $1,165,000 | 0.29% |
WEBER ALAN W | 200,000 | $432,000,000 | 0.19% |
Zebra Capital Management LLC | 73,910 | $160,000 | 0.18% |
RBF Capital, LLC | 569,323 | $1,230,000 | 0.14% |
Leap Investments LP | 69,496 | $150,000 | 0.08% |
Connor, Clark & Lunn Investment Management Ltd. | 4,387,038 | $9,476,000 | 0.06% |
CHICAGO EQUITY PARTNERS LLC | 519,315 | $1,122,000 | 0.05% |